tpo-ras + anti-cd20 antibody

This is a combination therapy consisting of a thrombopoietin receptor agonist (TPO-RA) and an anti-CD20 monoclonal antibody. TPO-RAs, such as eltrombopag, avatrombopag, hetrombopag, and romiplostim, stimulate platelet production by activating the thrombopoietin receptor on megakaryocytes in the bone marrow. Anti-CD20 antibodies—such as rituximab or ortuzumab—target CD20 on B cells to deplete these cells via immune-mediated mechanisms including complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This combination is being investigated primarily for immune thrombocytopenia (ITP), especially in patients who are refractory to first-line therapies like corticosteroids or immunoglobulins[1][3][4]. The rationale is that TPO-RAs increase platelet production while anti-CD20 antibodies reduce autoantibody-producing B cells that drive ITP pathology.

Other names

TPO-RA + rituximab